Key factors
sym | VERU |
exch | US |
MCap | 216.64M |
Beta | -0.19 |
EPS | -0.7 |
Div date | 2014-04-28 |
Yesterday
sym | VERU |
exch | US |
close | 1.275 |
50 Day MA | 0.729 |
200 Day MA | 0.860 |
52 Week High | 1.92 |
52 Week Low | 0.36 |
Target Price | 2.75 |
Market Cap Mln | 216.64 |
Share statistics
Shares Outstanding | 146.38M |
Shares Float | 112.00M |
Percent Institutions | 40.39 |
PercentInsiders | 14.10 |
SharesShort | 9908.93K |
Short Ratio | 7.79 |
Shares Short Prior Month | 9504.18K |
Short Percent | 7.569 |
Income
Revenue TTM | 15.92M |
Revenue Per Share TTM | 0.177 |
Quarterly Revenue Growth YOY | -14.5 |
Gross Profit TTM | 30.59M |
EBITDA | -75.0M |
Diluted Eps TTM | -0.7 |
earning
Operating Margin TTM | -4.11 |
EPS Estimate Current Quarter | -0.06 |
EPS Estimate Current Year | -0.26 |
EPS Estimate Next Quarter | -0.06 |
EPS Estimate Next Year | -0.3 |
Earnings Share | -0.7 |
Dividend
Dividend Date | 2014-05-07 |
Last Split Date | 0000-00-00 |
business
Enterprise Value Ebitda | -3.23 |
Enterprise Value Revenue | 12.22 |
Book Value /share | 0.353 |
Price Book MRQ | 4.283 |
Price Sales TTM | 13.96 |
ReturnOnAssetsTTM | -0.51 |
ReturnOnEquityTTM | -1.24 |
Sector
Gic Group | Household & Personal Products |
Gic Industry | Personal Care Products |
Gic Sector | Consumer Staples |
Gic Sub Industry | Personal Care Products |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US92536C1036 |
CIK | 863894 |
Code | VERU |
CUSIP | 976817106 |
Employer Id Number | 39-1144397 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | Domestic |
info
Fiscal Year End | September |
ForwardPE | 117.64 |
Full Time Employees | 189.0 |
IPODate | 1990-07-19 |
International Domestic | Domestic |
MostRecent Quarter | 2024-03-31 |
Contact
Name | Veru Inc |
Address | 2916 North Miami Avenue, Miami, FL, United States, 33127 |
Country Name | USA |
Phone | 305 509 6897 |
Web URL | https://verupharma.com |
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.